Assessment of the MANTA closure device in real-life transfemoral transcatheter aortic valve replacement: A single-centre observational study.

Background: Vascular complications increase morbidity and mortality in transcatheter aortic valve replacement (TAVR). Data involving suture-based percutaneous vascular closure devices (VCDs) have been extensive. Although promising, data regarding the efficacy and safety of the MANTA VCD (Teleflex) are scarce.

Aorto-iliac angiography as a screening tool in selecting patients for transfemoral aortic valve implantation with the Edwards SAPIEN bioprosthesis.

Aims: Transcatheter aortic valve replacement (TAVR) is a promising therapeutic option for patients with severe aortic stenosis (AS) considered at too high risk for conventional aortic valve replacement. The balloon-expandable Edwards valve can be implanted using either the transfemoral or transapical routes, depending on arterial ilio-femoral suitability. The aim of the study was to evaluate the usefulness of ilio-femoral angiography as an initial screening tool for TAVR using the transfemoral approach with the Edwards SAPIEN valve.

Early improvement of left ventricular function after implantation of a transcutaneous aortic valve: a tissue Doppler ultrasound study.

Introduction: The long-term effects of surgical treatment for aortic narrowing in left ventricular (LV) remodelling have been well described. The immediate benefit after release of obstruction is unknown.

Method And Results: Nineteen patients with significant and symptomatic aortic stenosis underwent transcutaneous implantation of an aortic valve.

[Percutaneous treatment of aortic stenosis].

Degenerative aortic stenosis is the most frequent valvular disease in developed countries. The reference treatment is surgical valve replacement but one third of the patients are not eligible for surgery. Alternative options have been recently proposed using transcatheter valve implantation (transfemoral or trans-apical approaches) in this subset of patients.

Transcatheter aortic valve implantation: technical aspects, results and indications.

The development of the percutaneous heart valve (PHV) may become a primary therapeutic modality for the high risk and inoperable patients with critical symptomatic aortic stenosis. The first human percutaneous aortic valve implant was performed by our group in April 2002. To date, more than 500 Cribier-Edwards-PHV have been implanted worldwide using arterial trans-femoral or trans-apical approach.